Skip to main content
. 2014 Jan 16;110(5):1155–1162. doi: 10.1038/bjc.2013.826

Figure 3.

Figure 3

Clinical activity of panobinostat and imatinib in GIST. (A) Water fall plot of the relative change in SUV of baseline scans compared with the scans at the end of cycle 1. (B) FDG-PET-CT images of a patient with advanced metastatic GIST at baseline after imatinib run-in (left) and after 3 weeks panobinostat (right) resulting in a partial metabolic remission.